King's CorVue Needs More Work, Could Be Best-In-Class With The Right Data
Executive Summary
King could springboard its imaging agent CorVue to best-in-class status with further data - including a more diverse patient population, increased study of the comparator drug, and additional data on angiography - FDA's Cardiovascular and Renal Drug Products Advisory Committee told the agency